Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.58 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 4/20 | 0.52 |
| ▸ | DRD4 | P21917 | 4/20 | 0.52 |
| ▸ | DRD3 | P35462 | 3/20 | 0.52 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19207211 | 0.86 | HRH3 (0.52) | HRH3CARM1PRMT6DRD2DRD4 | |
| SCHEMBL7445090 | 0.79 | HRH3 (0.53) | HRH3CARM1PRMT6DRD2DRD4 | |
| SCHEMBL8391744 | 0.78 | HRH3 (0.67) | HRH3CARM1PRMT6DRD2DRD4 | |
| SCHEMBL427694 | 0.78 | CARM1 (0.60) | HRH3CARM1PRMT6DRD2DRD4 | |
| SCHEMBL1307334 | 0.78 | EPHX2 (0.44) | HRH3 | |
| SCHEMBL11394514 | 0.77 | CHRM2 (0.59) | HRH3DRD2DRD4DRD3HTR2A | |
| SCHEMBL5537846 | 0.77 | CARM1 (0.68) | HRH3CARM1PRMT6DRD2DRD4 | |
| SCHEMBL4855546 | 0.77 | HRH3 (0.74) | HRH3CARM1PRMT6DRD2DRD4 | |
| SCHEMBL7404606 | 0.77 | HRH3 (0.48) | HRH3CARM1PRMT6DRD2DRD4 | |
| SCHEMBL7474765 | 0.76 | HRH3 (0.52) | HRH3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053457-B2 | 3-imidazolyl-indoles for the treatment of proliferative diseases | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| EP-2142535-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis Ag (CH) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008119741-A2 | 3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2008-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125064-A1 | 3-Imidazolyl-Indoles for the Treatment of Proliferative Diseases | MDM4, TP53, MDM2 | HRH3 1388/4885CARM1 913/4885PRMT6 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.